Table 2.
Higher expression of Th1 response- and inflammation-associated genes in negative tumors
| Marker | All tumors (n = 78) |
ER positive (n = 52) |
ER negative (n = 26) |
Individual | Corrected | |||
|---|---|---|---|---|---|---|---|---|
| Folda | Range | Fold | Range | Fold | Range | p | p | |
| CCL2 | 1.9 | (0.2–20.9) | 1.5 | (0.2–20.9) | 2.7 | (0.5–17.2) | 0.01 | NS |
| CCL3 | 3.5 | (0.2–50.1) | 3.4 | (0.3–50.1) | 4.1 | (0.2–12.1) | 0.70 | NS |
| CCL4 | 4.3 | (0.1–29.7) | 3.9 | (0.1–21.0) | 6.8 | (0.1–29.7) | 0.01 | NS |
| CCL5 | 2.7 | (0.2–35.5) | 1.7 | (0.2–23.4) | 4.6 | (0.5–35.5) | 0.00 | 0.01 |
| CCL20 | 3.2 | (0.1–199.8) | 2.3 | (0.1–39.0) | 6.4 | (0.7–199.8) | 0.01 | NS |
| GNLY | 1.2 | (0.1–28.0) | 0.7 | (0.1–4.8) | 4.6 | (0.9–28.0) | 0.00 | 0.00 |
| IFNγ | 1.2 | (0.1–19.3) | 0.8 | (0.1–19.3) | 1.8 | (0.1–11.9) | 0.02 | NS |
| IL1B | 9.9 | (0.3–71.8) | 9.9 | (0.3–71.8) | 9.6 | (1.5–58.2) | 0.89 | NS |
| IL6 | 0.4 | (0.0–13.6) | 0.3 | (0.0–8.4) | 0.8 | (0.1–13.6) | 0.02 | NS |
| IL8 | 0.7 | (0.0–13.4) | 0.5 | (0.0–12.6) | 1.8 | (0.1–13.4) | 0.00 | 0.04 |
| IL12 | 1.1 | (0.1–12.7) | 0.8 | (0.1–10.5) | 2.4 | (0.5–12.7) | 0.00 | 0.00 |
| IL17Ab | 12.4 | (1.5–1214.9) | 7.1 | (2.8–634.3) | 26.2 | (1.5–1214.9) | 0.00 | 0.00 |
| IL21 | 23.5 | (0.1–1007.0) | 15.0 | (0.1–305.2) | 64.4 | (1.7–1007.0) | 0.00 | 0.00 |
| IL23 | 2.9 | (0.1–191.1) | 2.1 | (0.1–10.6) | 8.1 | (1.0–191.1) | 0.00 | 0.00 |
| IL32 | 3.2 | (0.2–35.8) | 2.5 | (0.2–10.5) | 8.7 | (1.3–35.8) | 0.00 | 0.00 |
| TNFα | 6.1 | (0.4–53.9) | 5.5 | (0.4–42.0) | 7.4 | (1.0–53.9) | 0.48 | NS |
| TBX21 | 0.8 | (0.0–7.9) | 0.6 | (0.0–7.9) | 1.4 | (0.2–6.1) | 0.00 | 0.00 |
NS not significant, IL interleukin, CCL chemokine (C–C motif) ligand, GNLY granulysin, IFNγ interferon gamma, TNFα tumor necrosis factor alpha, TBX21 T-box 21
a
Represent median fold values (with range in brackets). Differences across the ER subtypes were analyzed using Mann–Whitney U test
b
IL17A was detected in 39 tumors(17 ER positive, 22 ER negative)